A probe from the UK’s competition watchdog has resulted in an £8 million (US$9.7 million) payment from Aspen Pharma to Britain’s National Health Service (NHS).
The South African drugmaker agreed to make the payment, as part of a wider package, after the Competition and Markets Authority uncovered “anti-competitive arrangements” regarding the supply of the life-saving medicine fludrocortisone.
The drug is primarily used to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.
The payment to the NHS and the firm’s admission of illegality, as well as an additional fine of up to £2.1 million (US$2.5 million), will forestall any legal action from the UK government.
Full Content: Gov UK